Prostate cancer treatment may change how men process common sleep aid

NCT ID NCT03436745

Terminated Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looked at how the sleep drug zolpidem (Ambien) is processed in men with prostate cancer before and after they start hormone therapy that lowers testosterone. Researchers compared these results to healthy women, since women are known to have higher drug levels. The goal was to see if hormone changes affect drug exposure, which could lead to better dosing. The study was terminated early and enrolled only 12 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zolpidem (Ambien)
What this could lead to: If successful, this study could help doctors determine safer, more accurate doses of zolpidem for men on hormone therapy and for women.
What could go wrong: This is a very small, early pilot study that was terminated, so results are limited. It does not test a new treatment, only how the body processes an existing drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.